Published On: Mon, Oct 6th, 2014

Fluoropharma Medical Inc. (OTCMKTS:FPMI): Announced Abstract Acceptance

Fluoropharma Medical Inc. (OTCMKTS:FPMI)’s abstract highlighting key facts from CardioPET related Phase II clinical trial got accepted for oral presentation. This presentation will allow the company to share key findings at the Annual Congress of the EANM (European Association of Nuclear Medicine). The conference will be organized in Gothenburg, Sweden from October 18 to October 22, 2014. The ongoing Phase II study is aiming at evaluating myocardial perfusion and fatty acid uptake in CAD (coronary artery disease) patients.

Fluoropharma reported that the abstract will be presented on October 19, 2014 during a session on ‘Cardiovascular System: Cardiac PET Imaging.’ Dr. Fabian Demeure, author of the abstract, will make a presentation at 11:30 a.m. sharing initial data related to CardioPET’s image quality, optimal timing and safety profile.

Fluoropharma Medical Inc. (OTCMKTS:FPMI)’s Chairman and CEO, Thijs Spoor, expressed that the company will present the CardioPET data for the first time in Europe. CardioPET is demonstrating significant results through Phase II and given its clinical trials success it will help improve the current diagnostic capabilities. Spoor mentioned that novel imaging agents like CardioPET are urgently needed to facilitate more accurate diagnosis at the earliest stages. Early diagnosis could help improve patient outcomes through more effective treatment and cost saving for healthcare system.

Fluoropharma Medical Inc. (OTCMKTS:FPMI)’s CardioPET is designed for use as a cardiac imaging agent. This PET imaging product can prove to be effective alternative to existing diagnostic tests. The ongoing Phase II trial is assessing diagnostic performance and safety profile of CardioPET as compared to the current standards like angiography and SPECT myocardial perfusion imaging agents. Fluoropharma is conducting this study in Belgium at multiple clinical sites.

Fluoropharma focuses on the development of PET imaging products to diagnose cardiac disease at the cellular and molecular levels. The company has licensed proprietary technology from the Massachusetts General Hospital and was pursuing development of novel PET imaging agents. These breakthrough agents are designed to target myocardial cells.

© Copyright 2016 OTC News Magazine. All rights reserved.